Nobel Prize for RIBOSOME researchers

Three scientists who showed how the information encoded on strands of DNA is translated into thousands of proteins that make up living matter will share the 2009

-->

WHO backs anti-diarrhoea vaccine

The World Health Organization says a vaccine which can prevent a diarrhoea and vomiting virus should be given to all children as a routine vaccination.

Rotavirus causes more than 500,000 diarrhoeal deaths and two million hospitalisations a year among children.

Over 85% of deaths occur in developing countries in Africa and Asia.

International experts welcomed the WHO's recommendations, based on new research, but UK scientists have said the vaccine is too costly.

'Milestone'

The WHO's Strategic Advisory Group of Experts (SAGE) made its recommendations after new data from clinical trials.

The clinical trial, which involved a range or organisations including the Global Alliance for Vaccines and Immunisations (GAVI) and drug company GlaxoSmithKline (GSK), which makes the vaccine plus researchers in South Africa and Malawi, found that rotavirus vaccine significantly reduced severe diarrhoea episodes.

The WHO's Dr Thomas Cherian, said: "This is a tremendous milestone in ensuring that vaccines against the most common cause of lethal diarrhoea reach the children who need them most."

But the WHO said, because there were other causes of diarrhoea, it was also important to improve water quality, hygiene, and sanitation and ensure oral rehydration solutions and zinc supplements were available.

Dr Tachi Yamada, president of the Global Health Program at the Bill and Melinda Gates Foundation, said: "This WHO recommendation clears the way for vaccines that will protect children in the developing world from one of the most deadly diseases they face.

"We need to act now to deliver vaccines to children in Africa and Asia, where most rotavirus deaths occur."

Dr Julian Lob-Levyt, chief executive officer of GAVI, said: "This represents another important step in our ability to achieve significant impact on under-five deaths in the world's poorest communities and make progress towards the Millennium Development Goals.

"We are extremely excited about the potential to offer African and Asian countries funding to introduce rotavirus vaccines."

'Price cut'

There are around 130,000 episodes of gastroenteritis caused by rotavirus each year in the UK.

Around 12,700 children are hospitalised, and four die each year.

The Joint Committee on Vaccination and Immunisation, which advises the government, said in February that it would only consider recommending the vaccine if its price were significantly reduced.

In February, the JCVI said: "Rotavirus vaccination would reduce the incidence of rotavirus in the population.

"However, the cost-effectiveness analysis showed that, based on current vaccine prices, universal vaccination of young children significantly exceeded the commonly accepted threshold for cost-effective healthcare interventions.

"Introduction of rotavirus vaccines may only become cost-effective if the vaccine price is reduced significantly."

Professor Andrew Hall, chairman of the JCVI, said the committee always kept vaccines under review and considered new information.

'Breakthrough' in malaria fight

-->

Australian scientists have identified a potential treatment to combat malaria.

Researchers in Melbourne believe their discovery could be a major breakthrough in the fight against the disease.
The malaria parasite produces a glue-like substance which makes the cells it infects sticky, so they cannot be flushed through the body.
The researchers have shown removing a protein responsible for the glue can destroy its stickiness, and undermine the parasite's defence.
The malaria parasite - Plasmodium falciparum - effectively hijacks the red blood cells it invades, changing their shape and physical properties dramatically.
Among the changes it triggers is the production of the glue-like substance, which enables the infected cells to stick to the walls of the blood vessels.
This stops them being pased through the spleen, where the parasites would usually be destroyed by the immune system.
Painstaking tests
The Australian team developed mutant strains of P. falciparum, each lacking one of 83 genes known or predicted to play a role in the red cell remodeling process.
Systematically testing each one, they were able to show that eight proteins were involved in the production of the key glue-like substance.
Removing just one of these proteins stopped the infected cells from attaching themselves to the walls of blood vessels.
Professor Alan Cowman, a member of the research team at the Walter and Eliza Hall Institute of Medical Research, said targeting the protein with drugs - or possibly a vaccine - could be key to fighting malaria.
"If we block the stickiness we essentially block the virulence or the capacity of the parasite to cause disease," he said.
Malaria is preventable and curable, but can be fatal if not treated promptly. The disease kills more than a million people each year. Many of the victims are young children in sub-Saharan Africa.

Malaria parasites 'resist drugs'

International scientists say they have found the first evidence of resistance to the world's most effective drug for treating malaria.

They say the trend in western Cambodia has to be urgently contained because full-blown resistance would be a global health catastrophe.
Drugs are taking longer to clear blood of malaria parasites than before.
This is an early warning sign of emerging resistance to a disease which kills a million people every year.
Until now the most effective drug cleared all malaria parasites from the blood within two or three days but in recent trials this took up to four or five days.
It is unclear why the region has become a nursery for the resistance - but the local public health system is weak, and the use of anti-malaria drugs is not properly controlled.
Drug defence
The artemesinin family of drugs is the world's front-line defence against the most prevalent and deadly form of malaria.
Two teams of scientists, working on separate clinical trials, have reported seeing the disturbing evidence that the drugs are becoming much less effective.
There is particular concern because previous generations of malaria drugs have been undermined by resistance which started in this way, in this part of the world, our correspondent reports.
The World Health Organization warned in 2006 there was a possibility the malaria parasite could develop a resistance to artemesinin drugs, and that there was particular concern about a decreased sensitivity to the drug being seen in South East Asia.
It urged drug firms to stop selling artemesinin on its own in order to prevent resistance building up.
Early results from two studies by US and UK teams have both revealed the early stages of resistance.
Between a third and a half of patients in the US study saw delayed clearance of the malaria parasite.
In the UK study, patients in the Cambodia arm of the trial took almost twice as long to clear the parasite as a comparison group in Thailand.
Professor Nick Day, director of the Mahidol-Oxford Tropical Medicine Research Unit which is carrying out the UK study, said: "Twice in the past, South East Asia has made a gift, unwittingly, of drug resistant parasites to the rest of the world, in particular to Africa," he said.
"That's the problem. We've had chloroquine and SP (sulfadoxine pyrimethamine) resistance, both of which have caused major loss of life in Africa," he said in reference to earlier generation anti-malarial drugs.
"If the same thing happens again, the spread of a resistant parasite from Asia to Africa, that will have devastating consequences for malaria control," he said.
Prof Brian Greenwood, Professor of Tropical Medicine (Oxford Handbook of Tropical Medicine (Oxford Handbooks Series)) at the London School of Hygiene and Tropical Medicine, described the findings as a matter for concern, even though treatment still worked if a full course of artemisinin combination therapy (ACT) was taken.
"There is currently no need for panic but it would be serious if these partially resistant parasites reached Africa where great gains in malaria control are currently being made using ACTs and insecticide-treated bed nets," he said.
Health systems
Cambodia has long been a laboratory for malaria investigators and a nursery of anti-malaria drug resistance.
Alongside a weak public health system and poorly-controlled drug use, there are many fake drugs, produced by international criminals.
These fakes often contain a small amount of the real drug to fool tests, which can also help to fuel resistance.
Those working to control malaria are calling for urgent action to contain this emerging resistance.
If it strengthens and spreads, they warn, many millions of lives will be at risk. About half the world's population faces exposure to the disease.

Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) is molecular biological technique used for amplifying (creating copies of) DNA without the use of living organisms such as E coli, yeast. It is used in medical and biological research laboratories for detection of hereditary diseases, diagnosis of infectious diseases, identification of genetic fingerprints, cloning of genes and paternity testing.

The concept of PCR was at first put forward by H Ghobind Khorana et al in 1971 but is seemed to be impractical before gene sequencing and viable thermostable DNA polymerase. Later, after 15 years in 1986 Kary Mills developed the PCR technique. PCR is a process by which DNA is artificially multiplied through repeated cycles of duplication in the presence of DNA polymerase.

The PCR process was patented by Cetus Corporation where Kary Mills worked where he developed the technique. Taq polymerase enzyme was also covered by the patent. The pharmaceutical company Hoffmann-La-Roche purchased the right to patent in 1992 and currently holds them.

DNA polymerase occurs naturally in living organisms and functions to create copies of DNA when cell divides. It functions by binding to single stranded DNA and creating complementary strand. The original concept of PCR technique developed by Mills uses the enzyme in vitro. Double stranded DNA was separated into two single strands by heating at 96 degree C. However, at this high temperature, DNA polymerase was destroyed and required to be replenished after heating stage of each cycle. Thus, it required great deal of time, large amount of DNA polymerase and continued attention throughout the PCR process.

Later, this PCR process was modified by using DNA polymerase obtained from thermophilic bacteria that grow in geysers at 110 degree C. This DNA polymerase was thermostable and do not break down when the reaction mixture was heated to separate strands.

The first thermostable DNA polymerase was obtained from Thermus aquaticus and called Taq polymerase. One of the disadvantages of this Taq polymerase was that it sometimes maked mistakes while making copies of DNA leading to mutation of DNA sequences since it lacked 3’-5’ proofreading exonuclease enzyme. The polymerase Pwo and Pfu obtained from Archaea contained exonuclease enzyme and reduced the mistakes while making copies of DNA. The combination of Taq and Pfu is available now a days that provides both fidelity and accurate amplification of DNA.

PCR amplifies short, well defined DNA fragment. It requires a single gene or just a par of gene. As opposed to living organism, PCR can make copies of only short DNA fragment upto 10 kb ie 1000 base pairs. DNA is double stranded and therefore it is measured as complementary DNA building block (nucleotides as base pairs).

PCR requires
DNA template containing the region of DNA fragment to be amplified
Two primers determining the beginning and end of DNA fragment to be amplified
DNA polymerese to make copies of DNA fragment to be amplified
Nucleotide from which DNA polymerase synthesize DNA strand
Buffer for creating optimum chemical environment for DNA polymerase to perform

PCR is carried out in thermal cycler. It is a machine that cools and heats the reactions tubes within it in precise temperature that is required for each step of the reaction. Evaporation of the reaction mixture is prevented by placing heated lid on reaction tube or by placing thin oil layer on the reaction mixture.

Primer
DNA fragment to be amplified is determined by selecting the primer. Primers are artificial, short DNA strands upto 50 nucleotides that exactly match the beginning and end of the DNA strand to be amplified. They anneal with DNA template at these beginning and end points and DNA polymerase binds and begins synthesis of DNA strand.

The choice of the length of the primers and their melting temperature depends on several considerations. Melting temperature of primer- not to be confused with the melting temperature of DNA at firs step of PCR- is the temperature at which half of the primer binding sites would be occupied. Melting temperature increases with the length of the primer. Short primers would anneal at several points on the long DNA template resulting non specific copies. On the other hand, length of the primer is limited by melting temperature at which it melts. High melting temperature above 80 degree C will cause problem since the DNA polymerase is less active at this high temperature. The optimum length of primer is 20 – 40 nucleotide wit melting temperature of 60 – 75 degree C.

PCR has a series of 20-30 cycles and each cycle consists of 3 steps-
1st step- Double stranded DNA is heated at about 94-96 degree C to separate the strands. This step is called denaturation and breaks apart the hydrogen bond that binds together two DNA strands. Prior to the first cycle, DNA is denatured for extended time period in order to ensure that both template DNA and primers are separated into single strand. The time of this step is usually 1-2 minute/s.

2nd step- After denaturation, temperature is lowered so that primer anneals with the single stranded DNA. This step is called annealation. Temperature of this step depends on the primers and is usually 5 degree C below their melting temperature. Wrong temperature at this step causes primer not to bind with DNA template or binding at random. Time of this step is 1-2 minute/s.

3rd step- After annealation, DNA polymerase has to fill the missing strands. DNA polymerase binds at annealed primer and works its way along the DNA fragment. This step is called elongation. Temperature of this step depends on DNA polymerase. However, time of this step depends both on the DNA polymerase itself and the length of DNA fragment to be elongated. Usually by the rule of thumb, the time of this step is 1 minute for every 1,000 bp.

The PCR product is identified by its size using Agarose gel electrophoresis. The sixe of PCR product is determined by comparing it with DNA ladder.

Uses of PCR
Genetic fingerprinting
Detection of hereditary disease
Cloning of genes
Analysis of ancient DNA
Paternity testing
Genotyping of specific mutation
Mutagenesis
Comparison of gene expression

Genetic fingerprinting is a forensic technique to identify a person by comparing his/her DNA with a sample e.g:- urine, semen, saliva, blood, hair from crime scene can be genetically compared to the blood of suspect.
Genetic fingerprint is unique except for identical twins
Genetic relationship can be determined by comparing two or more genetic fingerprints for paternity test
A slight variation of this technique can be used to determine evolutionary relationship between organisms.

Gram positive bacteria
aerobic coccus- Staphylococcus, Streptococcus, Enterococcus
anaerobic coccus- Peptostreptococcus

aerobic / facultative anaerobic rod- Bacillus, Corynebacterium, Lactobacillus, Mycobacterium, Listeria, Nocardia
anaerobic rod- Clostridium, Actinomyces

Gram negative bacteria
aerobic coccus- Neisseria

aerobic rod- Pseudomonas
facultative anaerobic rod- Escherichis, Proteus, Klebsiella, Shigella, Salmonella, Vibrio, Haemophilus, Bordetella, Brucella, Yersinia, Pasteurella
anaerobic rod- Bacteroid, Fusobacterium
Microaerophilic rod- Campylobacter

aerobic spirochaete- Leptospira
anaerobic spirochaete- Borrelia, Treponema

About Influenza

Influenza is a viral infection of birds and mammals that affects the respiratory system. The virus typically causes symptoms such as fever, sore throat and muscle pain, but severe cases can lead to pneumonia, nerve & brain damage Does Stress Damage the Brain?: Understanding Trauma-Related Disorders from a Mind-Body Perspective and even death. In the developed world, individuals at high risk of contracting influenza are usually vaccinated but as different strains of the virus mutate (a phenomenon known as ‘antigenic drift’ Genetic Drift: Genetic drift. Population bottleneck, Founder effect, Allopatric speciation, Antigenic drift, Small population size, Hardy¿Weinberg principle, ... theory of molecular evolution, Ronald Fisher), vaccines from one year may be ineffective the next, so there is a constant need for evolving, novel therapies to be developed. The virus spreads around the world in seasonal epidemics. In a typical year there are between three and five million cases of severe illness and up to half a million deaths globally. The cost of influenza in the US is over $10billion a year in lost productivity and associated medical treatment. Currently the H5N1 strain of avian influenza Avian Influenza H5N1 Strain Virus Chicken Fowl Photographic Poster Print, 18x24 poses the greatest global threat, and a pandemic is projected to cost hundreds of billions of dollars.